Natera, Inc. (NTRA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 9:20 AM EDT
Company Participants
Mike Brophy – Chief Financial Officer
Conference Call Participants
Elizabeth Koslosky – Goldman Sachs Group, Inc., Research Division
Presentation
Elizabeth Koslosky
Goldman Sachs Group, Inc., Research Division
All right. Thank you. Well, good morning, everyone. I’m Evie Koslosky, the Life Science Tools and Diagnostics Analyst here at Goldman Sachs. And I’m joined here today by Mike Brophy, CFO of Natera.
Mike Brophy
Chief Financial Officer
Good morning. Thanks for having me.
Question-and-Answer Session
Elizabeth Koslosky
Goldman Sachs Group, Inc., Research Division
Of course. So I guess just to start things off, you came off a really strong Q1. You cleared the 1 million unit milestone for the first time in a single quarter, raised full year revenue guide. Maybe walk us through a high level what you saw in the quarter and then how things have changed since then?
Mike Brophy
Chief Financial Officer
Yes. Well, we had a great quarter. I mean, we had another record Signatera volume growth quarter. We had an absolutely massive women’s health quarter as a record on a number of different levels just in terms of volumes. Realized pricing was outstanding across the board, COGS per unit was actually outstanding across the board, if you look at the specific unit economics and the COGS per test that we delivered, had a very strong set of data that we just released at ASCO, I guess, last weekend, circa last weekend, that was very encouraging. So we’re on a fantastic trajectory here.
Looking into the rest of the year, we significantly bumped the revenue guide. We bumped the gross margin guide. We even bumped the R&D guide this year, which I viewed as a positive because what that meant was that
You must be logged in to post a comment Login